J&J To Exit Spinoff Kenvue With Latest Stake Sale

By Reuters
Share this article
J&J To Exit Spinoff Kenvue With Latest Stake Sale

Tylenol maker Kenvue has said that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.

Based on Kenvue stock's last close, the offering of 182.3 million shares would be worth about $3.75 billion, according to Reuters calculation.

Kenvue's shares were down 1.2% in premarket trading. J&J shares were largely unchanged.

J&J finalised the biggest shake-up in its 137-year history to focus on its pharmaceutical and medical devices businesses. The company in May last year sold 172.8 million shares in Kenvue to raise $3.8 billion (€3.5 billion), and lowered its stake over the next three months.

J&J will exchange its holding to Goldman Sachs and J.P. Morgan Securities for its debt, Kenvue said. Goldman Sachs, J.P. Morgan and BofA Securities are the joint lead book-running managers.


The Band-Aid maker has focused on its 15 priority brands since the spinoff and earlier this month said it would cut 4% of its global workforce.

Kenvue's shares are down 4.6% so far this year, and nearly 8% from its listing price in May 2023.

Quarterly Report

Last week, the company beat Wall Street estimates for first-quarter profit and said it would cut 4% of its global workforce amid efforts to expand its key brands.

The company said it targets pre-tax gross savings of about $350 million (€325.1 million) annually by 2026 through the cost-cutting programme, but will incur $275 million (€255.4 million) each in restructuring expenses in 2024 and 2025.

The self-care segment – which includes cough and cold medicine such as Tylenol and Benadryl – recorded $1.70 billion (€1.6 billion) in net sales, up 3.5% year-on-year.

Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.